Janux Therapeutics (JANX) News Today $29.06 +0.11 (+0.38%) Closing price 04:00 PM EasternExtended Trading$28.68 -0.38 (-1.31%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Quinn Opportunity Partners LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)Quinn Opportunity Partners LLC purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,000 shares of the company's stock, valued at approximately $1,071,000. A number of otherApril 14 at 6:24 AM | marketbeat.comFmr LLC Acquires 845,266 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Fmr LLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,669,941 shares of the company's stock afterApril 12 at 5:41 AM | marketbeat.com9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Sei Investments Co.Sei Investments Co. bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,378 shares of the company's stockApril 12 at 3:18 AM | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Reaches New 1-Year Low - Time to Sell?Janux Therapeutics (NASDAQ:JANX) Reaches New 12-Month Low - What's Next?April 11, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,136,332 shares of the company's stock afterApril 10, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 18,509 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)ADAR1 Capital Management LLC grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 142.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,509 shares of the company's stock after purchasiApril 9, 2025 | marketbeat.comWellington Management Group LLP Acquires 520,898 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Wellington Management Group LLP raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 3,592.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 535,396 shares of the company'sApril 9, 2025 | marketbeat.comSpringhill Fund Asset Management HK Co Ltd Invests $1.59 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)Springhill Fund Asset Management HK Co Ltd purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 29,600 shares of the companApril 8, 2025 | marketbeat.comTrexquant Investment LP Buys New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX)Trexquant Investment LP purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 65,858 shares of the cApril 8, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 2,519.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 497,287 shares of the company's stock after purchasing an addiApril 8, 2025 | marketbeat.comJanux Therapeutics: What's My Inflection Point?April 7, 2025 | seekingalpha.comJanux Therapeutics: What's My Inflection Point?April 7, 2025 | seekingalpha.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Rhenman & Partners Asset Management ABRhenman & Partners Asset Management AB raised its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 59.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 170,000 shares of the company's stock after acquiring an additionalApril 7, 2025 | marketbeat.comPamalican Asset Management Ltd Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)Pamalican Asset Management Ltd purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 25,000 shares of the company's stock, valued at approximately $1,338,000. Several otherApril 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Schroder Investment Management GroupSchroder Investment Management Group boosted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 111.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 156,874 shares of the company's stock after aApril 6, 2025 | marketbeat.comJanux Therapeutics: Buying For The Promising Pipeline, Holding For The BuyoutApril 5, 2025 | seekingalpha.comJanux Therapeutics (NASDAQ:JANX) Trading Up 7.5% - Still a Buy?Janux Therapeutics (NASDAQ:JANX) Trading Up 7.5% - Time to Buy?April 4, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Reaches New 12-Month Low - Should You Sell?Janux Therapeutics (NASDAQ:JANX) Reaches New 12-Month Low - Here's What HappenedApril 4, 2025 | marketbeat.comPictet Asset Management Holding SA Purchases New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Pictet Asset Management Holding SA acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 384,797 shaApril 2, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Down 7.1% - What's Next?Janux Therapeutics (NASDAQ:JANX) Shares Down 7.1% - Here's WhyApril 1, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Buy" from AnalystsJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been given a consensus rating of "Buy" by the twelve research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assMarch 31, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Hits New 52-Week Low - Here's WhyJanux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low - Time to Sell?March 29, 2025 | marketbeat.com10 Best Small-Cap Stocks to Buy Before They ExplodeMarch 28, 2025 | insidermonkey.comIs Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?March 28, 2025 | msn.comIs Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?March 27, 2025 | msn.comFirst Week of JANX November 21st Options TradingMarch 26, 2025 | nasdaq.comEntryPoint Capital LLC Makes New $655,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)EntryPoint Capital LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 12,225 shares of the company's stock, valued at approximately $655,000. SevMarch 26, 2025 | marketbeat.comSwiss National Bank Buys 38,400 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Swiss National Bank raised its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 94.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 79,100 shares of the company's stock after buying an additional 38,400 shares during the period. SMarch 26, 2025 | marketbeat.comJanux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | msn.comWe're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To GrowMarch 25, 2025 | finance.yahoo.com13,498 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Magnetar Financial LLCMagnetar Financial LLC bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,498 shares of the company's stock, valued at approximatelyMarch 23, 2025 | marketbeat.comProficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)Proficio Capital Partners LLC acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 25,271 shares of the company's stock, valued at aMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Charles Schwab Investment Management Inc. boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 273,135 shares of the company's stock after buying anMarch 21, 2025 | marketbeat.comIs Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?March 20, 2025 | insidermonkey.comJanux Therapeutics, Inc. (NASDAQ:JANX) Holdings Raised by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 492.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 205,167 shares of theMarch 16, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Up 8.9% - Should You Buy?Janux Therapeutics (NASDAQ:JANX) Trading 8.9% Higher - Still a Buy?March 13, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)Victory Capital Management Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 715.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,409 shares of the company's stock after buyingMarch 13, 2025 | marketbeat.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comJanux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low - Should You Sell?Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - Here's WhyMarch 11, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up Following Insider Buying ActivityJanux Therapeutics (NASDAQ:JANX) Shares Gap Up on Insider Buying ActivityMarch 10, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Director Buys $3,418,590.12 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) Director Ra Capital Management, L.P. acquired 110,206 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.March 8, 2025 | marketbeat.comRa Capital Management, L.P. Acquires 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.March 8, 2025 | marketbeat.comJANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and MoreMarch 7, 2025 | nasdaq.comHC Wainwright Expects Lower Earnings for Janux TherapeuticsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for Janux Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now forecasts that the compaMarch 7, 2025 | marketbeat.comJanux Therapeutics (JANX) Projected to Post Quarterly Earnings on FridayJanux Therapeutics (NASDAQ:JANX) will be releasing earnings before the market opens on Friday, March 14, Financial Modeling Prep reports.March 7, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $107,188.10 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.March 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Andrew Hollman Meyer Sells 3,334 SharesMarch 6, 2025 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Buy" by BrokeragesShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, ten have givenMarch 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending RecentlyMarch 5, 2025 | insidermonkey.comJanux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending RecentlyMarch 5, 2025 | msn.com Remove Ads Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼1.520.78▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼84▲JANX Articles Average Week Remove Ads Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LEGN News Today BPMC News Today SRPT News Today TLX News Today AXSM News Today KRYS News Today NUVL News Today GRFS News Today ELAN News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
